NEW YORK, April 18 - In a sign that RNAi is truly creating a buzz in the life sciences community, Ribozyme Pharmaceuticals announced Wednesday that it was changing its name to Sirna Therapeutics, and changing its stock symbol to RNAI.
Already have a GenomeWeb or 360Dx account?Login Now.
360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.
The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.
In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.
Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.